Detailed Narrative
Attruby Commercial Momentum and Differentiation
Attruby demonstrated strong commercial momentum in Q2 FY26, growing 23% and being the fastest-growing brand in its space. This growth was primarily driven by the treatment-naive segment, with new patient starts consistent with Q1. The company expects continued first-line market growth and aims to increase its share, supported by expanding clinical differentiation data, including real-world evidence and newly documented renal protective effects.
Kidney Protective Effects of Attruby
New data published in Circ: Heart Failure showed Attruby driving the first-ever early and sustained direct kidney protective effects in ATTR cardiomyopathy, including eGFR slope improvement and urinary albumin-to-creatinine ratio reduction. This effect, which mirrors early clinical outcomes, suggests Attruby may protect both heart and kidney simultaneously. Intriguingly, acute eGFR dips on Attruby were associated with better outcomes (HR 0.42 for all-cause mortality/CV hospitalization), contrasting with placebo, and the company plans further studies in orphan kidney indications.
Impact of CARDIO-TTRansform Results
The failure of the CARDIO-TTRansform study for eplontersen to meet its primary efficacy endpoint reinforced stabilization as the first-line standard of care for ATTR cardiomyopathy. BridgeBio believes this outcome strengthens the case for stabilizers first, particularly for Attruby as a near-complete stabilizer, and may position it favorably in the second-line setting if monotherapy knockdown continues to underperform.
Late-Stage Pipeline Advancements
All three late-stage programs—BBP-418 for LGMD2I, encaleret for ADH1, and infigratinib for achondroplasia—have advanced into regulatory review. BBP-418 and encaleret received priority review from the FDA, with PDUFA dates set for November 27, 2026, and May 8, 2027, respectively. Infigratinib's NDA was submitted following positive Phase III results published in The New England Journal of Medicine, targeting mid-2027 approval.
Encaleret's Broader Opportunity in Chronic Hypoparathyroidism
Beyond ADH1, encaleret is being developed for chronic hypoparathyroidism (CHP), a condition affecting 200,000 patients in the U.S. and EU. Management believes this opportunity is overlooked, citing the need for an oral option that corrects both hypocalcemia and hypercalciuria, and addresses PTH-mediated bone issues. The RECLAIM-HP Phase III trial has commenced screening, with results expected in 18 months, offering a potential blockbuster opportunity.
Infigratinib's Differentiation in Achondroplasia
Infigratinib, an oral FGFR3-targeted therapeutic for achondroplasia, offers a significant advantage over injectable competitors due to its convenient once-daily capsule formulation. It also demonstrated functional differentiation in Phase III, including a statistically significant 0.37 standard deviation improvement in arm span, the first placebo-controlled benefit of its kind. The company anticipates achieving over 65% peak market share in this space.
Financial Position and Capital Allocation
BridgeBio closed a $1 billion preferred equity investment, bringing its cash, cash equivalents, and marketable securities to approximately $1.7 billion as of July 1, 2026. This capital provides a significant runway to fund operating activities, support the three upcoming launches, and continue investing in Attruby's commercial growth while maintaining financial discipline.